#USA #Cambridge, Massachusetts #Kytopen #Flowfect Tx #Excellos

Innovative Partnership for Non-Viral Cell Therapy

Kytopen Corp., known for its advancements in continuous flow cellular engineering, has teamed up with Excellos, Inc., a leading cell therapy contract development and manufacturing organization (CDMO). This strategic collaboration aims to revolutionize manufacturing processes for non-viral cell therapies by leveraging Kytopen's cutting-edge Flowfect Tx® platform alongside Excellos' unique donor-to-dose manufacturing model.

Exploring Synergies in Technology

The primary focus of their collaboration is to assess how the Flowfect Tx® platform can enhance Excellos' processing capabilities. This involves combining Kytopen's innovative engineering technology with Excellos' proficiency in deep cell characterization, providing a solid foundation for evaluating the possibilities of increasing process consistency and scalability while maintaining high cell quality.

Tom VanCott, CEO of Excellos, expressed enthusiasm about the partnership, stating that Kytopen's state-of-the-art technology promises to complement their existing workflows efficiently. Similarly, Kevin Gutshall, Chief Commercial Officer at Kytopen, emphasized the partnership's goal of ensuring that advanced therapies can be a part of everyday healthcare practices.

A Commitment to Patient-Focused Solutions

Both Kytopen and Excellos share a strong commitment to speeding up the transition from scientific advancements to real-world manufacturing solutions that prioritize patient needs. Their shared vision reflects a desire to simplify complex processes in order to achieve better outcomes for developers of cell therapies.

The initial steps in this collaboration will involve identifying scientific synergies and operational efficiencies, with hopes that subsequent efforts can converge as their development priorities align. By focusing on proof-of-principle initiatives, both companies seek a deeper understanding of the biological and procedural complexities within cell therapy production that remain unidentified.

Future Prospects in Cell Therapy Manufacturing

As they embark on this journey, Kytopen and Excellos are not only looking to innovate but also to redefine the norms of cell therapy manufacturing. The partnership could open up new avenues for scalable production methodologies, enabling more effective treatments and therapies to reach those in need quickly.

The path towards discovering the full potential of non-viral cell therapies is widening through this innovative collaboration. As they work together, the industry can anticipate significant advancements that might very well transform the therapeutic landscape.

By combining their strengths, Kytopen and Excellos are poised to make significant contributions to the future of healthcare, potentially leading to impactful advances in the development and manufacture of cell-based therapeutics that address patients' needs across the globe.

About Kytopen

Kytopen, based in Cambridge, Massachusetts, is pioneering non-viral continuous flow cellular engineering technologies that optimize cell therapy production, capable of delivering substantial quantities of engineered cells efficiently. Their Flowfect® technology caters to a wide range of cell types and therapeutic applications.

About Excellos

Based in San Diego, Excellos specializes in cell therapies and offers GMP services that minimize variability while enhancing reproducibility and success in therapeutic workflows, driving innovation and efficiency in the production of cell-based therapies. For more information, visit their websites at Kytopen and Excellos.